A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
Gilead Sciences
Newave Pharmaceutical Inc
MacroGenics
Acerta Pharma BV
AstraZeneca
Xencor, Inc.
Astellas Pharma Inc
Mustang Bio
Novartis
Power Life Sciences Inc.
Aziende Chimiche Riunite Angelini Francesco S.p.A
Fore Biotherapeutics
AstraZeneca
MedImmune LLC
MedImmune LLC
Morphotek
INSYS Therapeutics Inc
MedImmune LLC